X4 Pharmaceuticals, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6.5M | $2.6M | $0 | $0 | $0 | $3.0M | $0 | $0 |
| Cost of Revenue | $5.8M | $797.0K | $0 | $0 | — | — | — | — |
| Gross Profit | $743.0K | $1.8M | $0 | $0 | — | — | — | — |
| Gross Margin | 11.4% | 69.3% | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $72.7M | $81.6M | $72.0M | $61.1M | $50.6M | $41.9M | $30.2M | $20.3M |
| SG&A Expense | $43.5M | $61.5M | $35.5M | $27.0M | $24.7M | $20.9M | $17.6M | $8.7M |
| Operating Income | $-86.9M | $-36.4M | $-107.5M | $-87.6M | $-85.1M | $-59.9M | $-51.7M | $-29.1M |
| Operating Margin | -1,336.7% | -1,400.0% | — | — | — | -1,995.8% | — | — |
| Interest Expense | — | — | $5.8M | $4.0M | $3.6M | $2.7M | $2.1M | $720.0K |
| Pretax Income | $-79.2M | $-37.1M | $-101.1M | $-93.8M | $-88.7M | $-62.0M | $-52.8M | $-33.3M |
| Income Tax Expense | $41.0K | $310.0K | $78.0K | $28.0K | $17.0K | $148.0K | $0 | $0 |
| Net Income | $-79.2M | $-37.5M | $-101.2M | $-93.9M | $-88.7M | $-62.1M | $-52.8M | $-33.3M |
| Net Margin | -1,218.4% | -1,440.4% | — | — | — | -2,071.0% | — | — |
| EPS (Basic) | $-1.87 | $-5.59 | $-17.07 | $-0.25 | $-0.33 | $-0.26 | $-0.39 | $-6.60 |
| EPS (Diluted) | $-1.87 | $-5.59 | $-17.07 | $-0.25 | $-0.33 | $-0.26 | $-0.39 | $-6.60 |
| Shares Outstanding (Basic) | 42.3M | 6.7M | 5.9M | 381.2M | 309.0M | 240.9M | 193.5M | 4.2M |
| Shares Outstanding (Diluted) | 42.3M | 6.7M | 5.9M | 381.2M | 309.0M | 240.9M | 193.5M | 4.2M |
| Dividends Per Share | — | — | — | — | — | — | — | — |